Androgen receptor as potential therapeutic target in metastatic endometrial cancer
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
// Ingvild Løberg Tangen 1, 2 , Therese Bredholt Onyango 1, 2 , Reidun Kopperud 1, 2 , Anna Berg 1, 2 , Mari K. Halle 1, 2 , Anne M. Øyan 3, 4 , Henrica M.J. Werner 1, 2 , Jone Trovik 1, 2 , Karl Henning Kalland 3, 4 , Helga B. Salvesen 1, 2, * , Camilla Krakstad 2, 5, * 1 Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Norway 2 Department of Gynecology and Obstetrics, Haukeland University Hospital, Norway 3 Centre for Cancer Biomarkers, Department of Clinical Medicine, University of Bergen, Norway 4 Department of Microbiology, Haukeland University Hospital, Norway 5 Centre for Cancer Biomarkers, Department of Biomedicine, University of Bergen, Norway * These authors contributed equally to this work Correspondence to: Camilla Krakstad, email: camilla.krakstad@uib.no Keywords: androgen receptor, endometrial cancer, biomarker, survival Received: April 06, 2016 Accepted: June 13, 2016 Published: June 30, 2016 ABSTRACT Purpose: The expression and involvement of estrogen (ER) and progesterone receptor (PR) is extensively studied in endometrial cancer. Androgen receptor (AR) is a hormone receptor less studied in female cancers, and we here aim to investigate the expression level of AR in endometrial cancer precursor lesions, primary tumors and metastases, and its potential as therapeutic target. Results: Expression of AR was observed in 93% of hyperplasias, but only in 41% of non-endometrioid tumors. Compared to estrogen and progesterone receptor AR is more commonly expressed in metastatic lesions, and AR status is discordant in primary and metastatic lesions in a large proportion of cases. AR protein level was significantly associated with survival ( P < 0.001), and a calculated AR to ERα ratio identified a subgroup of patients with particular poor outcome. The anti-androgen enzalutamide may have a growth inhibitory effect in endometrial cancer cells based on experiments with primary endometrial tumor cells. Materials and Methods: 718 primary endometrial cancers and 298 metastatic lesions (from 142 patients) were investigated for expression of AR in relation to survival, clinical and histopathological data. Protein levels were investigated by immunohistochemistry and reverse phase protein array; mRNA levels by DNA oligonucleotide microarray. The effect of androgen stimulation and inhibition was tested on primary endometrial tumor cells. Conclusions: A large proportion of metastatic endometrial cancer lesions express AR, which may be a potential target in these patients. Treatment targeting AR may be of particular benefit in patients with high AR levels compared to ERα levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
Evidence of androgen action in endometrial and ovarian cancers
Gibson, D. A., Simitsidellis, I., Collins, F., & Saunders, P. T. K. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0551 · Cited by 73 · cited 1×
“It is expressed in several tissues, including the uterus, where its role is largely unknown [10, 11].”
Cited by
Androgens and endometrium: new insights and new targets
Simitsidellis, I., Saunders, P. T. K., & Gibson, D. A. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.09.022 · Cited by 107
Konings, G. F., Cornel, K. M., Xanthoulea, S., Delvoux, B., Skowron, M. A., Kooreman, L., Koskimies, P., Krakstad, C., Salvesen, H. B., van Kuijk, K., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5004 · Cited by 26
Self-citationGjorgoska, M., Taylor, A. E., Smrkolj, Š., & Rižner, T. L. (2025) · Cancers · doi:10.3390/cancers17101679 · Cited by 1
“Moreover, endometrial tumors, especially endometrioid ones, are known to express steroid-metabolizing enzymes and receptors [44–50], and to form locally androgens, 11-oxyandrogens and estrogens [35,51], suggesting that this intra-tumoral activity may also contribute to the improved diagnostic…”
Metadata
- Authors
- Tangen, I. L., Onyango, T. B., Kopperud, R., Berg, A., Halle, M. K., Øyan, A. M., Werner, H. M. J., Trovik, J., Kalland, K. H., Salvesen, H. B., & Krakstad, C.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-06-30
- Volume
- 7
- Issue
- 31
- Pages
- 49289-49298
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2465663488
- Cited by
- 68
- References
- 4
- FWCI
- 9.90
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Androgen receptor as potential therapeutic target in metastatic endometrial cancer. https://app.cochat.ai/papers/10.18632/oncotarget.10334
- The paper
- Tangen, I. L., Onyango, T. B., Kopperud, R., Berg, A., Halle, M. K., Øyan, A. M., Werner, H. M. J., Trovik, J., Kalland, K. H., Salvesen, H. B., & Krakstad, C. (2016). Androgen receptor as potential therapeutic target in metastatic endometrial cancer. Oncotarget. https://doi.org/10.18632/oncotarget.10334
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.